Cervical cancer vaccines jointly win UK Prix Galien
This article was originally published in Scrip
The UK Prix Galien Medal for Innovation has been awarded jointly to the two marketed cervical cancer vaccines,Sanofi-Pasteur MSD's Gardasil andGlaxoSmithKline's Cervarix. Other products highly commended for their innovation werePfizer's Champix andMS&D's Januvia, and commended products were Roche's Herceptin and MabThera, and Wyeth's Tygacil. The Prix Galien for orphan drug development was won by Novartis for Exjade, which is used to treat chronic iron overload in patients with thalassaemias. Commended orphans were GlaxoSmithKline's Atriance, Novartis's Tasigna, Bristol-Myers Squibb's Sprycel, Wyeth's Torisel and Encysive's Thelin. The judging panel was chaired by Sir Michael Rawlins, the chairman of the National Institute for health and Clinical Excellence.
You may also be interested in...
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.